Ameritas Investment Partners Inc. continued to hold its stake in PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,615 shares of the medical research company’s stock at the end of the second quarter. Ameritas Investment Partners Inc.’s holdings in PerkinElmer were worth $178,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Envestnet Asset Management Inc. grew its holdings in PerkinElmer by 28.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock valued at $115,000 after buying an additional 434 shares in the last quarter. Acrospire Investment Management LLC grew its holdings in PerkinElmer by 185.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,300 shares in the last quarter. LS Investment Advisors LLC grew its holdings in PerkinElmer by 2.1% in the 2nd quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock valued at $196,000 after buying an additional 60 shares in the last quarter. Carret Asset Management LLC acquired a new position in PerkinElmer in the 2nd quarter valued at $210,000. Finally, Capital Asset Advisory Services LLC acquired a new position in PerkinElmer in the 2nd quarter valued at $222,000. 92.46% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have recently issued reports on PKI shares. Wells Fargo & Company started coverage on PerkinElmer in a report on Thursday, July 13th. They set a “market perform” rating and a $72.00 target price on the stock. Zacks Investment Research lowered PerkinElmer from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $67.00 target price on shares of PerkinElmer in a report on Tuesday, September 26th. Robert W. Baird reissued a “buy” rating and set a $72.00 target price on shares of PerkinElmer in a report on Friday, October 20th. Finally, Cowen and Company reissued a “hold” rating and set a $70.00 target price on shares of PerkinElmer in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $68.14.

PerkinElmer (NYSE:PKI) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.67 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.67. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The business had revenue of $547.00 million during the quarter, compared to analysts’ expectations of $554.14 million. During the same period in the previous year, the business earned $0.67 earnings per share. The firm’s revenue was up 2.0% on a year-over-year basis.

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Thursday, January 18th. PerkinElmer’s payout ratio is 8.46%.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/ameritas-investment-partners-inc-has-178000-holdings-in-perkinelmer-inc-pki/1675165.html.

PerkinElmer Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.